Page 1 - BULLETIN HSB 2021

INSIDE THIS ISSUE
1
NEW APPROACH DRUGS IN MOH FORMULARY
CONTENT PAGE
NO GENERIC NAME DETAILS
• New Approach
1 Daclatasvir 30mg & Approved indication(s): Drugs in MOH
60mg Tablet Formulary 1
To be used in combination with other medicinal products for the
Prescriber category: treatment of chronic hepatitis C (CHC) in adults. • Drug Updates
A/KK • New COVID-19
Dose: 2
Variants
60mg once daily, to be taken orally with or without meals.
• National COVID-19
2 Sofosbuvir 400mg Approved indication(s):
Immunisation
Tablet
To be used in combination with other medicinal products for the Programme 3
Prescriber category: treatment of chronic hepatitis C (CHC) in adults. • Malaysia’s COVID-
A/KK 19 Vaccine Portfolio
Dose:
• FAQ regarding
400mg once daily, taken orally with food. Sofosbuvir should be used
COVID-19 Vaccines 4
in combination with other medicinal products. Monotherapy of
Sofosbuvir is not recommended. • Pharmacy Activities
3 Azelastine Approved Indications(s): 2020 5
Hydrochloride
Symptomatic treatment of moderate to severe allergic rhinitis and
137mcg and
rhino-conjunctivitis in adults and children 12 years and older where EDITORIAL BOARD:
Fluticasone
use of a combination (intranasal antihistamine and glucocorticoid) is Advisor:
Propionate 50mcg
appropriate.
Nasal Spray Pn Noraini Bt Ahmad
Dose: (Ketua Pegawai Farmasi)
Prescriber Category:
A* One actuation in each nostril twice daily. Chief Editors:
4 Ribociclib 200 Tablet Approved indication(s):
Pn Tan Siew Chin (PF UF52)
Prescriber Category: In combination with: An aromatase inhibitor for the treatment of
A* (Oncologist only) postmenopausal women, with hormone receptor (HR)-positive, Pn Ng Mei Ying (PF UF48)
human epidermal growth factor receptor 2 (HER2)-negative advanced Pn Kanagesvary a/p
or metastatic breast cancer, as initial endocrine-based therapy. Nagarajan (PF UF44)
Dose: Editorial Member:

600mg daily for 21 consecutive days followed by 7 days off
Pn Nurwahidah bt Asat
treatment. Can be taken with or without food.
(PF UF41)

DRUG UPDATES 1

NO GENERIC NAME AMENDMENT DETAILS
1 Indacaterol Maleate 110 mcg and
Glycopyrronium Bromide 50mcg
Inhalation Change of category prescriber Prescribing restriction in primary care facilities:
from: A* to A/KK
2 Tiotropium 2.5mcg and Olodaterol Patients with inhaler coordination problem
2.5mcg Inhalation

References:-
1. Ministry of Health (MOH). (2020, Disember). Pindaan FUKKM Bil 02/2020.
1